Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Autolus Therapeutics (AUTL) Gross Profit (2024 - 2025)

Autolus Therapeutics' Gross Profit history spans 2 years, with the latest figure at -$1.0 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 90.83% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached -$21.0 million, down 1567.81%, while the annual FY2025 figure was -$21.0 million, 1555.96% down from the prior year.
  • Gross Profit reached -$1.0 million in Q4 2025 per AUTL's latest filing, up from -$7.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $10.1 million in Q1 2024 to a low of -$11.4 million in Q4 2024.